We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




First Animal-Free Screening Platforms to Predict Toxic Kidney Injury

By LabMedica International staff writers
Posted on 18 Oct 2015
Print article
Image: Renal proximal tubule-like cells (nucleus: blue, cytoplasm: red) derived from induced pluripotent stem cells that have been left untreated (top) or treated with aristolochic acid (bottom), an herbal nephrotoxic compound widely used in traditional Chinese medicine and other herbal remedies, which is now banned in many countries. (Photo courtesy of Singapore’s Institute of Bioengineering and Nanotechnology).
Image: Renal proximal tubule-like cells (nucleus: blue, cytoplasm: red) derived from induced pluripotent stem cells that have been left untreated (top) or treated with aristolochic acid (bottom), an herbal nephrotoxic compound widely used in traditional Chinese medicine and other herbal remedies, which is now banned in many countries. (Photo courtesy of Singapore’s Institute of Bioengineering and Nanotechnology).
In a biotechnological advancement involving human induced pluripotent stem cells (h-iPSCs), researchers have developed the first animal-free screening platforms capable of predicting a compound’s toxicity on the human kidney. The new platforms may provide a reliable and efficient tool in evaluating safety of novel compounds and ingredients, as is required in chemical and pharmaceutical as well as food and consumer care industries.

A team led by Dr. Daniele Zink, principal research scientist at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) of Singapore’s Agency for Science, Technology, and Research (A*STAR), has developed cell-based renal screening platforms that can accurately predict nephrotoxicity. Previous platforms were based on human primary renal proximal tubular cells or similar cells derived from human embryonic stem cells (hESCs). However, primary cells directly harvested from the human body are associated with various problems, including limited availability, while use of hESCs may give rise to ethical and legal concerns. Therefore, the researchers worked on an approach using h-iPSCs, which could also be used to develop patient- and disease-specific models to provide better understanding of renal disease and facilitate development of personalized therapies and drugs.

To realize this breakthrough, the scientists invented an effective way of producing human renal cells from h-iPSCs and combined this with machine learning methods that improved the automated and accurate prediction of nephrotoxicity. In addition, this novel platform correctly identified injury mechanisms, which can help advance understanding of the tested compounds.

“Our new kidney screening platforms will be very useful for many industries,” said Prof. Jackie Y. Ying, IBN Executive Director. Due to their role in the elimination of drugs and other foreign compounds, the kidneys are a main target for compound-induced toxicity. Approximately 20% of hospital and community acquired cases of acute kidney injury were caused by such compounds. A drug’s toxic effect on the kidney would typically be discovered in late stages of drug development or even after the product has been marketed. Therefore, the ability to determine toxicity earlier in the development phase would be of great interest.

Among the many challenges associated with using animal models to predict the nephrotoxicity of a new compound are the long time required, high costs involved, unreliable results due to inter-species differences, as well as ethical issues. Therefore, researchers have focused their efforts on developing cell-based screening methods. Animal-free screening methods are now also mandatory for cosmetic companies selling products in the EU, India, and Israel after implementation of animal testing bans in these countries. Validated and accepted animal-free methods for predicting nephrotoxicity are currently not commercially available.

Dr. Zink said, “We have developed the fastest and most efficient protocol for generating kidney cells from induced pluripotent stem cells. Within 8 days, it yielded highly pure kidney cells that were suitable for compound screening. We also worked closely with Dr. Lit-Hsin Loo’s team from the Bioinformatics Institute, which developed the data analysis procedures and machine learning methods that allow us to predict drug-induced nephrotoxicity with great accuracy. We were further able to identify injury mechanisms and drug-induced cellular pathways by using automated cellular imaging. We hope that our work will contribute to the development of safer products.” The team plans to work with partners to further validate and apply the platforms.

The study, by Kandasamy K et al. was published July 2015 in the journal Scientific Reports.

Related Links:

Institute of Bioengineering and Nanotechnology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.